NATERA INC (Common Stock) – ticker 45E (NTRA)
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.
Why Natera Is My Favorite Stock Idea for the Rest of 2026
It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions
NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results
Natera gets buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue guidance. NTRA's Q1 revenue grew 38% YoY, with test volumes up 18.5%, reflecting strong operational momentum and market demand. Despite ongoing unprofitability, margin improvements and analyst consensus point toward profitability by FY28, supported by upward earnings revisions.
Natera Expands Austin Operations With New Sequencing Facility
NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.
